Biocryst Pharmaceuticals Inc. (BCRX) Stock Could Soon Reward Patient Investors

Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) is -2.34% lower on its value in year-to-date trading and has touched a low of $4.82 and a high of $10.52 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCRX stock was last observed hovering at around $5.32 in the last trading session, with the day’s gains setting it 0.53%.

Currently trading at $5.85, the stock is 4.64% and -0.68% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.47 million and changing 9.96% at the moment leaves the stock -13.48% off its SMA200. BCRX registered -42.98% loss for a year compared to 6-month loss of -17.26%. The firm has a 50-day simple moving average (SMA 50) of $5.19 and a 200-day simple moving average (SMA200) of -$13.42.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


The stock witnessed a -14.97% gain in the last 1 month and extending the period to 3 months gives it a 6.95%, and is 15.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.77% over the week and 5.61% over the month.

Profit margin for the company is -74.43%. Distance from 52-week low is 21.24% and -44.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-54.69%).

Biocryst Pharmaceuticals Inc. quarterly earnings per share for the current quarter are estimated at -$0.24 with sales reaching $90.01M over the same period.The EPS is expected to grow by 21.00% this year, but quarterly earnings will post 21.00% year-over-year. Quarterly sales are estimated to grow 13.20% in year-over-year returns.

Biocryst Pharmaceuticals Inc. (BCRX) Top Institutional Holders

315 institutions hold shares in Biocryst Pharmaceuticals Inc. (BCRX), with institutional investors hold 90.53% of the company’s shares. The shares outstanding are 204.81M, and float is at 198.47M with Short Float at 14.63%. Institutions hold 89.41% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 15.5 million shares valued at $109.09 million. The investor’s holdings represent 8.18% of the BCRX Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 15.09 million shares valued at $106.23 million to account for 7.96% of the shares outstanding. The other top investors are Baker Brothers Advisors, LLC which holds 12.71 million shares representing 6.71% and valued at over $89.48 million, while State Street Corporation holds 6.47% of the shares totaling 12.26 million with a market value of $86.34 million.

Biocryst Pharmaceuticals Inc. (BCRX) Insider Activity

A total of 2 insider transactions have happened at Biocryst Pharmaceuticals Inc. (BCRX) in the last six months, with sales accounting for 0 and purchases happening 2 times. The most recent transaction is an insider sale by SANDERS MACHELLE ,the company’sDirector. SEC filings show that SANDERS MACHELLE sold 4,000 shares of the company’s common stock on Jun 15 at a price of $7.98 per share for a total of $31920.0. Following the sale, the insider now owns 25611.0 shares.

Biocryst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jun 14 that Hutson Nancy J (Director) sold a total of 12,866 shares of the company’s common stock. The trade occurred on Jun 14 and was made at $8.04 per share for $0.1 million. Following the transaction, the insider now directly holds 81818.0 shares of the BCRX stock.

Still, SEC filings show that on Apr 03, Thackray Helen M. (Chief R&D Officer) disposed off 7,000 shares at an average price of $8.29 for $58030.0. The insider now directly holds 207,275 shares of Biocryst Pharmaceuticals Inc. (BCRX).

Biocryst Pharmaceuticals Inc. (BCRX): Who are the competitors?

The company’s main competitors (and peers) include CEL-SCI Corp. (CVM) that is trading -9.89% down over the past 12 months. Emergent Biosolutions Inc. (EBS) that is -87.98% lower over the same period.